|  | 
|  |  | 
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. | 
|   
 
    
    
    
Now that VVUS has traded below 10 it is time to start the new bear thread.  I am going to lower the bar a bit and see if we can't generate some bearish discussion.   In my practice there is almost zero interest in MUSE at this time. It doesn't look like that will change until Viagra is on the market a while and patients have had a chance to try it themselves. The attractiveness of a pill over a urethral suppository seems to be overwhelming. (I am considering setting aside at least one MUSE applicator for future generations of urologists so they can see what crude measures we had once for the treatment of impotence.) With the shorts perhaps looking to close out their profitable positions in the New Year will we see a bump up in the next week or two? What is a good entry point for a new short position? Or is it a slow slide from here? The company maintains that they are selling all they can produce but my experience suggests that we could see quite a dip in revenues in either of the next two quarters (beyond that caused by the announced drop in production), I am just not sure which. Will patients come back to MUSE in the future? Will the European market amount to anything? All in all it appears the VVUS rollercoaster still hasn't run its course and there is still a chance to make money shorting. Disclaimer: no current position in VVUS. | ||||||||||||||
| 
 
 | 
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings | 
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI | 
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |